Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Admission of Curidium Medica plc to AIM
REVERSE TAKEOVER & ADMISSION TO THE AIM


Embargoed: 07:00hrs, 6 July 2006

Curidium Medica plc (“the Company”)
(Formerly Cielo Holdings plc)

REVERSE TAKEOVER & ADMISSION TO THE AIM


Following the extraordinary general meeting (“EGM”) yesterday, the Company has successfully completed the reverse takeover of Curidium Limited (“Curidium”) and its shares have been admitted to trading on AIM today under the ticker symbol “CUR”.

The Company has successfully placed ordinary shares at 2 pence per share, raising £1.5 million (excluding expenses). The Company has 454,811,392 ordinary shares in issue with an initial market capitalisation, of £9.1 million at the placing price.

Overview of Curidium
Curidium has developed a novel and proprietary technology, Homomatrix, to establish the underlying mechanisms of human diseases. Curidium’s technology identifies different patient subgroups each having a distinct disease mechanism. This enables the generation of new diagnostic tools and medicines designed for a subgroup of patients and potentially offering improved safety and effectiveness. Curidium is focusing its core technology to diseases of the Central Nervous System (CNS).

Curidium has developed a pipeline of four clinical candidates to treat diseases, which were previously developed for other indications and the directors believe that Curidium’s approach to re-develop existing drugs as targeted medicines for the appropriate patient group may reduce clinical trial cost, development timelines and regulatory risks. Curidium’s directors believe it to be one of the most advanced companies identifying targeted medicines for CNS disorders and to generate shareholder value Curidium follows a diversified commercialisation model by building partnerships through 1) strategic research alliances and 2) product licensing agreements.

Dr Anne Bruinvels, CEO of Curidium Medica plc said,
“We are delighted with today’s admission to AIM and look forward to taking Curidium to the next stage of its development. Curidium is an exciting drug discovery and development company and the proceeds of the placing and the transaction enable us to build a greater bank of intellectual property and accelerate commercialisation of our existing assets.”

Placing Statistics

Placing Price

2p
Number of Ordinary Shares in issue immediately following the Placing and completion of the Acquisition
454,811,392

Market capitalisation at the Placing Price on Admission £9.1m

Approximate gross proceeds of the Placing receivable by the Company
£1.5m

AIM symbol on Admission
CUR
ISIN number GB0033550863


Change of Name
The Company’s name was changed to Curidium Medica plc from Cielo Holdings plc following approval at the EGM on 5 July 2006.

Change of Accounting Reference Date
The accounting reference date has been changed from 31 October to 31 December.

Change of Address of Registered Office
The Company’s registered office was changed from 14 Kinnerton Place South, London SW1X 8EH to Hamilton House, Mabledon Place, London WC1H 9BB.

Directors’ Shareholdings On Admission

Director % Shareholding on admission
Dr. Anne Bruinvels 20.4
Paul Foulger 0.8
Simon Cartmell 0.9
Dr. Barry Porter 6.7
Dr. Ann Hayes 0.1

Board of Directors
Simon Cartmell (Non-executive Chairman), aged 46
Simon has 24 years pharmaceutical, healthcare and biotechnology industry experience. He spent 17 years at GlaxoWellcome (now GlaxoSmithkline) in a number of UK and global roles, including therapy area director, infectious diseases and hepatitis and supply chain director, responsible for the global order fulfilment process from GlaxoSmithkline’s seven UK manufacturing sites. Simon joined Vernalis Group (formerly Vanguard Medica Plc) as chief operating officer in 1998 overseeing its acquisition of the neurosciences company Cerebrus plc in 1999. Following this he joined the main board of Celltech plc in the role of chief executive officer, of Celltech Pharmaceuticals, a major<


Publisher Contact Information:

Curidium Medica plc
+44 (0)20 7554 8790
investors@curidium.com

Company profile of Curidium Medica plc
Past press releases of Curidium Medica plc.

Data


27,526
Tech investments
From our Online Data Service
17,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.